Dorota Koníčková

Ms. Dorota Koníčková

Palacký University, Olomouc, Olomouc, Olomoucký Kraj, Czech Republic
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DKDorota Koníčková
Dorota Koníčková
KMKateřina Menšíková
Kateřina Menšíková
LTLucie Tučková
Lucie Tučková
EHEva Hényková
Eva Hényková
MSMiroslav Strnad
Miroslav Strnad
PKPetr Kanovsky
Petr Kanovsky
The understanding of neurodegenerative diseases, traditionally considered to be well-defined entities with distinguishable clinical phenotypes, has undergone a major shift over the last 20 years. The diagnosis of neurodegenerative diseases primarily requires functional brain imaging techniques or invasive tests such as lumbar puncture to assess cerebrospinal fluid. A new biological approach and research efforts, especially in vivo, have focused on biomarkers indicating underlying proteinopathy in cerebrospinal fluid and blood serum. However, due to the complexity and heterogeneity of neurodegenerative processes within the central nervous system and the large number of overlapping clinical diagnoses, identifying individual proteinopathies is relatively difficult and often not entirely accurate. For this reason, there is an urgent need to develop laboratory methods for identifying specific biomarkers, understand the molecular basis of neurodegenerative disorders and classify the quantifiable and readily available tools that can accelerate efforts to translate the knowledge into disease-modifying therapies that can improve and simplify the areas of differential diagnosis, as well as monitor the disease course with the aim of estimating the prognosis or evaluating the effects of treatment. The aim of this review is to summarize the current knowledge about clinically relevant biomarkers in different neurodegenerative diseases.

7 September 2023 in Journal of Neurochemistry
Verified
Journal Article
Open access
DKDorota Koníčková
Dorota Koníčková
KMKateřina Menšíková
Kateřina Menšíková
KKKateřina Klíčová
Kateřina Klíčová
MCMonika Chudáčková
Monika Chudáčková
MKMichaela Kaiserova
Michaela Kaiserova
PKPetr Kanovsky
Petr Kanovsky
Neurodegenerative diseases are a broad heterogeneous group affecting the nervous system. They are characterized, from a pathophysiological perspective, by the selective involvement of a subpopulation of nerve cells with a consequent clinical picture of a disease. Clinical diagnoses of neurodegenerative diseases are quite challenging and often not completely accurate because of their marked heterogeneity and frequently overlapping clinical pictures. Efforts are being made to define sufficiently specific and sensitive markers for individual neurodegenerative diseases or groups of diseases in order to increase the accuracy and speed of clinical diagnosis. Thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (CSF) and serum (α‐synuclein [α‐syn], tau protein [t‐tau], phosphorylated tau protein [p‐tau], β‐amyloid [Aβ], clusterin, chromogranin A [chromogrA], cystatin C [cyst C], neurofilament heavy chains [NFH], phosphorylated form of neurofilament heavy chains [pNF‐H], and ratio of tau protein/amyloid beta [Ind tau/Aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α‐synucleinopathies and four‐repeat (4R‐) tauopathies characterized by tau protein isoforms with four microtubule‐binding domains. In this study, we analyzed a cohort of 229 patients divided into four groups: (1) Parkinson's disease (PD) + dementia with Lewy bodies (DLB) (n = 82), (2) multiple system atrophy (MSA) (n = 25), (3) progressive supranuclear palsy (PSP) + corticobasal syndrome (CBS) (n = 30), and (4) healthy controls (HC) (n = 92). We also focused on analyzing the biomarkers in relation to each other with the intention of determining whether they are useful in distinguishing among individual proteinopathies. Our results indicate that the proposed set of biomarkers, when evaluated in CSF, is likely to be useful for the differential diagnosis of MSA versus 4RT. However, these biomarkers do not seem to provide any useful diagnostic information when assessed in blood serum. image

9 January 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
MKMichal Kaleta
Michal Kaleta
EHEva Hényková
Eva Hényková
KMKateřina Menšíková
Kateřina Menšíková
DFDavid Friedecky
David Friedecky
Aleš KvasničkaAleš Kvasnička
Aleš Kvasnička
Ondrej NovakOndrej Novak
Ondrej Novak
Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers (n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy (n = 13), and Alzheimer's disease (n = 25). Although these conditions have different pathologies and clinical symptoms, the discovery of new biomarkers is still important. The most statistically significant differences (with p-values of ≤0.05 to ≤0.0001) between the study cohorts were observed for three tryptophan metabolites: l-kynurenine in cerebrospinal fluid and 3-hydroxy-l-kynurenine and 5-hydroxy-l-tryptophan in blood serum. This led to the discovery of distinctive correlation patterns between the profiled cerebrospinal fluid and serum metabolites that could provide a basis for the differential diagnosis of neurodegenerative tauopathies and synucleinopathies. However, further large-scale studies are needed to determine the direct involvement of these metabolites in the studied neuropathologies, their response to medication, and their potential therapeutic relevance.

27 May 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
DKDorota Koníčková
Dorota Koníčková
DHD Hraboš
D Hraboš
KMK Menšíková
K Menšíková
LTL Tučková
L Tučková
MKM Kaleta
M Kaleta
PKP Kaňovský
P Kaňovský
Although it has been more than 200 years since Parkinson’s disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of α-synucleinopathies, which are all characterized by the pathological accumulation of aggregated α-synuclein (α-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), α-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson’s disease for over 100 years, and α-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of α-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological α-Syn protein at early stages and help develop effective disease-modifying treatment.

21 November 2024 in Nutrition Research Reviews
Verified
Journal Article
Open access
PDF file
DKDorota Koníčková
Dorota Koníčková
KMKateřina Menšíková
Kateřina Menšíková
LPLucie Plíhalová
Lucie Plíhalová
PKPetr Kanovsky
Petr Kanovsky
Coffee is one of the most known and consumed beverages worldwide. Only three species are used in commercial coffee production, that is, Coffea arabica L. (Arabica coffee), Coffea canephora Pierre ex A. Froehner (Robusta coffee) and Coffea liberica Hiern (Excelsa coffee). The world population consumes approximately two billion cups of coffee per day, making it an important commercial resource of bioactive compounds in world markets. High interest in coffee consumption described in the literature is due not only to its organoleptic properties (for example, desirable bitterness, amount of flavours and aromas) but also to its ability to stimulate the central nervous system. It is now known that there are more than 1000 compounds in coffee beverages, several of which have a bioactive activity. Recent studies show that consuming three to four cups of coffee per day, that is, moderate consumption according to the European Food Safety Authority, may be beneficial for health. The main objective of the proposed review is to provide a comprehensive overview of bioactive compounds in coffee and other caffeine-containing beverages and their effects on neurodegenerative proteinopathies.

9 June 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
DKDorota Koníčková
Dorota Koníčková
DHD. Hraboš
D. Hraboš
KMK. Menšíková
K. Menšíková
LTL. Tučková
L. Tučková
MKM. Kaleta
M. Kaleta
LKL. Tu Kov
L. Tu Kov
1. Alpha-synuclein: structure and function Alpha-synuclein (α-Syn) is a highly conserved small acidic protein with a molecular mass of 14 kDa, predominantly found in presynaptic terminals of neurons. It consists of three basic domains: an amphiphilic N-terminal region (NT; amino acid residues (AAA) 1-60), a central hydrophobic non-amyloid component domain (NAC; AAA 61-95), and an acidic C-terminal domain (CT; AAA 95-140), which contributes to The NT is an amphiphilic region consisting of amino acid (AAA) residues (AAA 1-60). The downstream region NAC (AAA 61-95) is hydrophobic and possibly involved in protein aggregation. The CT (AAA 95-140) contains several acidic AAAs, which are required for calcium binding and chaperone-like activity and play the role of a chaperone (regulation of synaptic vesicle binding, suggesting the physiological role for α-Syn in the membrane) [1]. In its natural state, α-Syn is natively unfolded and intrinsically disordered protein, but could potentially adopt helical conformations upon membrane binding is a monomeric protein characterized by low hydrophobicity and high charge. Similar to prion protein, α-Syn is an unfolded and intrinsically disordered protein. It is likely that physiologically, it exists as an equilibrium mixture of the unfolded monomeric form and helical forms, or oligomers [2,3].; thanks to its proposed ability to adopt an alpha-helix form when bound to cell membranes [3]. Although the biological function of α-Syn is not fully understood, evidence suggests that it plays an important role in modulating synaptic vesicle transport and neurotransmitter release during synapse formation While its exact biological role remains not fully understood, α-Syn is believed to regulate synaptic vesicle trafficking and neurotransmitter release [4].1.1. Alpha-synuclein: aggregation, seeding and prion-like spreading Under pathological conditions, α-Syn can self-aggregate, potentially propagate in a prion-like manner, and accumulate into tetramers to form tetrameric conformers (with an approximate size of ~58 kDa). The imbalance between the monomeric and tetrameric states makes it prone particularly susceptible to conformational changes, forming including the assembly of betafolded sheet-rich structures, which are typical of amyloid fibrils [1,5,6]. The conformationally Altered α-Syn molecule with beta-sheet aggregates structure tends to aggregate, engulfing normally structured α-Syn molecules and converting them into abnormally aggregated nonfibrillar and fibrillar forms. The as-of-yet poorly understood seeding process leads to the fibrillization of oligomers, with In addition, most seeding-efficient α-Syn forms often being small fibrillar aggregates (~ 50 nm) 50 nm long [7]. Oligomers are toxic, causing and induce cellular dysfunction, including synaptic, mitochondrial, lysosomal, and autophagic impairments, and can form pores in cell membranes incressinsg its permeability dysfunction.They have also been reported to create pores in cell membranes, thereby increasing membrane permeability and causing neurotoxicity [1]. α-Syn is proposed to spread in the nervous system in a prion-like manner, although the The detailed molecular pathways of underlying seeding, exocytosis, and the potential interaction of α-Syn with extracellular components are unclear. Misfolded α-Syn seeds are secreted into from donor cells to the interstitial compartment, either as free protein or in vesicles, and spread rapidly through neurons, aggregating in affected cells as naked protein or in vesicles.Experimental models show that the α-Syn seeds spread (at a rate of less than 24 hours) through neuronal cells and aggregate in affected neurons [1]. Furthermore, aggregates of α-Syn are detected in extracellular spaces, they circulate in biological fluids (CSF, blood) and could be detected in biological samples other than the central nervous system (skin, salivary and lacrimal glands, intestinal mucosa). The process of protein misfolding, aggregation, and spreading appears to begin decades before the onset of clinical symptoms [8,9]. Interestingly, α-Syn does not always aggregate and spread in the same manner. It is currently almost certain that the aggregated form α-Syn may have different conformational structures, usually referred to as conformational strains, which probably affect various brain regions and lead to different clinical phenotypes [5].Misfolded α-Syn can act as a seed that induces the conversion of normal cellular α-Syn, allowing the transcellular spread of Lewy bodies (LB) pathology in a prion-like manner [10].The aggregation of α-Syn follows a seeding/nucleation mechanism that is characterized by the progressive formation of oligomers, protofibrils, and fibrils that culminate in LB or glial cytoplasmic inclusions (GCIs). In the seeding/nucleation polymerization reaction, the first and rate-limiting step is the formation of a nucleus, which then forms large aggregates at the expense of the monomeric protein. The nucleus can serve as a seed to catalyze further polymerization, most likely remaining misfolded to the protein oligomer, which can be highly neurotoxic even before it grows into larger aggregates. A typical feature of the seeding/nucleation process is that adding preformed seeds can significantly accelerate the aggregation process by scooping soluble native protein into the growing aggregate. The seeding/nucleation mechanism provides a biochemical explanation for the propagation of misfolded proteins between cells and tissues.The molecular mechanisms of aggregate formation in the prion protein and α-Syn are similar.This suggests that misfolded proteins can spread between cells and tissues to initiate and propagate pathogenesis. A substantial body of evidence from the last decade demonstrates that misfolded α-Syn aggregates can move from cell to cell,...